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consisted of 65.75 Gy to the prostate gland+seminal vesicles 
(2.63 Gy/fx) and 45 Gy to the pelvic nodes (1.8 Gy daily) 
when needed, delivered in 25 fractions. All patients 
underwent daily image guidance with cone-beam computed 
tomography. Sixty-six percent of the patients received 
implanted gold markers (64/97). Acute and late 
gastrointestinal- and genitourinary toxicity was recorded 
according to the Common Terminology Criteria for Adverse 
Events 4.0. Chi-square test and univariate regression analysis 
were used to determine correlation of categorical and 
continuous data at the p<0.05 significance level. 
 
Results: During a median follow-up of 23 (range: 4-44) 
months, 7/97 biochemical failures (7%) were observed. The 
frequency of ≥Gr. 2 acute gastrointestinal (GI) and 
genitourinary (GU) toxicities were 8% (8/97) and 45% (44/97) 
including 6% Gr. 3 bladder urgency and nycturia (6/97). Late 
≥Gr. 2 GI toxicities of 14 % (13/97) were mainly rectal 
bleeding and chronic proctitits. Correlation was found 
between lymph node irradiation (p=0.008) and late rectal 
toxicities, while for other patient characteristics including 
the presence of gold markers (p=0.097) or smoking (p=0.99) 
did not appear to affect such adverse event. d univariate 
regression analysis were used to determine correlation of 
categorical and continuous data at the p<0.05 significance 
level. 
 
Conclusion: Our experiences suggest that moderate 
hypofractionation with SIB technique is safe with moderate 
acute side effects. Longer follow-up and higher number of 
patients is warranted to confirm these results in long term. 
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Purpose or Objective: Evaluate grade ≥ 2 overall late rectal 
and bladder toxicity in patients (pts) with localized prostate 
cancer (CaP) treated by IMRT. Identify predictors of 
radiation-induced toxicity and analyze biochemical 
progression free survival (bPFS). 
 
Material and Methods: A total of 276 pts were treated 
between 2000 and 2010 with 70Gy (10.8%), 74 Gy (63.9%) and 
80 Gy (25.3%), using static 5-field IMRT without pelvic 
irradiation. Short or longue-course deprivation (ADT) was 
prescribed in 25.4 % and 20.7%, respectively. The toxicity was 
described using the Common Terminology Criteria for Adverse 
Events (CTCAE) v4.0 scale. Cox regression models addressed 
tumor (T stage, Gleason score, PSA) and patient 
characteristics (age, diabetes, previous abdominal or pelvic 
surgery, transurethral prostate resection, anticoagulation 
treatment, hypertension, coronary insufficiency and 
International Prostate Symptom Score-IPSS) as well as 
dosimetric predictors of late grade ≥ 2 overall toxicity.  
An analysis of dosimetry data was only performed in the 74-
Gy arm. Our institutional HDV constraints for rectal wall 
(maximal dose ≤74 Gy, V68Gy <25%, V45Gy <45%) and bladder 
wall (maximal dose ≤74 Gy; V50Gy <40%, V65Gy <25%) were 
tested as potential predictors for late toxicity.  
Biochemical progression free survival was analyzed only in pts 
without ADT. 
 
Results: The median follow-up was 53.1 months (range, 6-
150). There was no grade ≥ 4 toxicity. The use of ADT was 
not found to be predictive. The 5-year rectal and bladder 
toxicity-free survival was 93.8 % (95% CI, 89.8%-96.2%) and 
75.2 % (95% CI, 68.7%-80.5%) respectively.  
In multivariate analysis (MvA) only the dose (80Gy vs 74 Gy 
and 70Gy) increased the risk of overall rectal toxicity (hazard 
ratio [HR]=2.96; 1.07- 8.20). The non-compliance to our 
constraints on rectal wall was not a significant predictor of 
rectal toxicity.  
IPSS at baseline ≥ 8 (hazard ratio [HR]=2.60;1.47 -4.62), 
delivered maximum dose (Dmax) ≥ 74Gy (HR=2.09;1.04 -4.17) 
and dose delivered in ≥ 2% of bladder (D2%) ≥ 73Gy 
(HR=3.33;1.37-8.07) were found to be predictors of bladder 
toxicity.  
The 5-year bPFS was 81.0% (74.5%; 86.0%). D’Amico low 
(HR=0.09; 0.01- 0.69]) and intermediate risk group (HR=0.49; 
0.28-0.88) as well as PSA nadir ≥ 0.2 ng/ml (HR =1.79; 1.01 -
3.21) were predictive of biochemical relapse. 
 
Conclusion: The rate of late rectal toxicity increased with 
higher doses, while Dmax ≥ 74Gy, D2% ≥ 73Gy and baseline 
IPSS ≥ 8 increased bladder toxicity. 
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Purpose or Objective: A relative new method to decrease 
the risk of rectal complications during prostate radiotherapy 
treatments consists of the implantation of a device, an 
absorbable hydrogel or saline filled balloon, between the 
prostate and the anterior rectum wall: so called rectum 
spacers (RS). Nevertheless the implantation of a RS is 
relatively expensive and invasive. Therefore a decision 
support system to identify beforehand whether a specific 
patient will benefit from a RS and whether it will be cost 
efficient would be very beneficial. We have developed a 
novel method to predict the CT images with a ‘virtual’ RS 
through non-rigid deformations based on a CT scan without 
RS to be integrated into a decision support system. 
 
Material and Methods: A patient dataset consisting of 16 
prostate cancer patients with CT imaging prior and 3-5 days 
after a gel RS implantation (SpaceOAR™ System, Augmenix 
Inc.) was used. The median inserted gel volume was 10.5 cc. 
Gel contours of the first 8 patients were used as a training 
set to derive the spatial deformation model of the RS. The 
contours of the RS were registered rigidly according to their 
centre and an average deformation map was created. The 
overlapping volumes of RS of different patients having a 
probability of >3 contour corresponded with a volume of 10 
cc, and was used to derive the deformation model of the RS. 
From this model, a deformation field was calculated that 
mimics the expansion of the RS between the prostate and the 
rectum. The CT images of the remaining 8 patients were used 
to validate the virtual RS model, for this the distance 
between the rectum and the prostate was compared for the 
virtual RS and the actual RS .  
 
Results: An example of the virtual RS is shown in the figure 
where the contours of the real RS and virtual RS show a good 
overlap (DICE = 0.63). The average minimum distances 
between the prostate and rectum of all 8 patients in the 
validation set increased with 3.7±2.4 (1SD) mm when the 
virtual RS was applied. For the real RS the average increase 
in minimum distance was 5.4±2.7 mm. The mean distances 
between the prostate and rectum without RS was 15.8±3.2 
mm, with the virtual RS this was 19.5±3.3 mm comparable to 
the real RS 22.0±4.3 mm. 
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Conclusion: We have developed a novel method to simulate a 
model based virtual RS that is a useful tool to identify 
patients with a potentially high benefit of a RS implantation. 
The volume of the virtual RS can be estimated through the 
use of different deformation fields. In future, a dose 
comparison study is necessary to extend into a full decision 
support system using the virtual RS approach. 
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Purpose or Objective: The escalation dose in the treatment 
of prostate cancer with external beam radiation therapy has 
proved the winning way in the biochemical control of the 
tumor. But the dose escalation to the whole prostate gland, 
which is considered as clinical target volume in external 
beam radiotherapy, is limited by the tolerance of the 
surrounding tissue. We have compared the toxicity profiles 
between patients treated with moderate hypofractionated 3-
dimensional conformal radiotherapy (3D-CRT) collated with 
volumetric-modulated arc therapy (VMAT), both with image-
guided radiotherapy (IGRT) by implanted fiducial markers in 
prostate gland (FMs) . 
 
Material and Methods: Between 2009 and 2011, 41 patients 
with prostate cancer were treated with 3DCRT-IG to a dose 
of 70 Gy 2.5 Gy/fr with daily online correction of the target 
position based on MV/MV. This group of patients was 
compared with a similar cohort of 39 patients who were 
treated between 2012 and 2014 with VMAT-IG to the same 
prescription dose with daily online correction of the target 
position based on MV/KV imaging. The clinical characteristics 
of these two patient populations are shown in Table 1. 
Radiation Therapy Oncology Group/European Organization for 
Research and Treatment of Cancer late morbidity 
RTOG/EORTC scores were used for acute and late effects. 
The median follow-up time was 3 years (range, 1-6 years). 
The rectal and bladder dose parameters were also included in 
the statistical analysis. 
 
 
 
Results: The rectal acute and late toxicity was low for both 
treatment groups and no significant reduction was observed 
for VMAT-IG patients compared with the 3DCRT-IG patients (P 
= 0.33). The likelihood acute genitourinary toxicity for the 
VMAT-IG and 3DCRT-IG cohorts were 14.5% and 18.0%, 
respectively (p = 0.61). Only for grade ≥ 2 acute 
genitourinary toxicity, the analyses showed a trend better 
but non significative result on behalf of VMAT-IG (P=0,09). 
Finally, no significant correlation was observed between the 
dose parameters and genito-urinary and rectal late toxicity 
The PSA relapse-free survival in according to Phoenix criteria 
(nadir plus 2 ng/ml) for 3D-CRT and VMAT were similar (98% 
vs. 96%; p = 0.34). 
 
Conclusion: Moderate hypofractionated IGRT is associated 
with a lower rate of genito-urinary and rectal toxicity for 
both treatment 3D-CRT and VMAT. These data suggest that, 
the placement of fiducial markers and daily online correction 
of target positioning may represent the preferred mode of 
external-beam radiotherapy delivery for the patients treated 
by definitive radiotherapy. 
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